Chen Cai1, Yi-Fan Xu2, Zhen-Jie Wu3, Qin Dong4, Min-Yu Li1, Jason C Olson5, Yaron M Rabinowitz6, Lin-Hui Wang7, Yinghao Sun2. 1. Department of Special Clinic, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China. 2. Department of Urology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China. 3. Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China. 4. Department of Nephrology, Shanghai Corps Hospital, Chinese People's Armed Police Forces, Shanghai, 201103, China. 5. Georgetown University School of Medicine, Washington, DC, 20007, USA. 6. Georgetown University School of Medicine, Washington, DC, 20007, USA. Yaron.Rabinowitz@gmail.com. 7. Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China. wanglinhuicz@163.com.
Abstract
PURPOSE: Renal cell carcinoma (RCC) is the most common cancer of kidney. Evidences have shown that RCC is sensitive to various immunotherapies. Tim-3 plays a role in suppressing Th1-mediated immune responses. However, no study has yet examined the effect of Tim-3 on tumor infiltrating lymphocytes (TILs) in RCC. METHODS: We investigated the expression and function of Tim-3 on TIL CD4+ T cells and TIL CD8+ T cells from 30 RCC patients. RESULTS: Levels of Tim-3 were significantly increased on both TIL CD4+ T cells and TIL CD8+ T cells and were associated with higher stages of the cancer. Also, GATA-3 and interferon gamma (IFN-γ) were down-regulated, whereas T-bet was up-regulated in TIL Tim-3+ T cells, indicating that Tim-3 expression defined a population of dysfunctional TIL Th1/Tc1 cells. Mechanism analyses showed that TIL Tim-3-expressing CD8+ T cells exhibited impaired Stat5 and p38 signaling pathway. Blocking the Tim-3 pathway restored cell proliferation and increased IFN-γ production in TIL CD4+ and CD8+ T cells of RCC. CONCLUSIONS: These results suggest that Tim-3 may be used as a novel target for increasing immune responses in RCC tumor microenvironment.
PURPOSE:Renal cell carcinoma (RCC) is the most common cancer of kidney. Evidences have shown that RCC is sensitive to various immunotherapies. Tim-3 plays a role in suppressing Th1-mediated immune responses. However, no study has yet examined the effect of Tim-3 on tumor infiltrating lymphocytes (TILs) in RCC. METHODS: We investigated the expression and function of Tim-3 on TIL CD4+ T cells and TIL CD8+ T cells from 30 RCCpatients. RESULTS: Levels of Tim-3 were significantly increased on both TIL CD4+ T cells and TIL CD8+ T cells and were associated with higher stages of the cancer. Also, GATA-3 and interferon gamma (IFN-γ) were down-regulated, whereas T-bet was up-regulated in TIL Tim-3+ T cells, indicating that Tim-3 expression defined a population of dysfunctional TIL Th1/Tc1 cells. Mechanism analyses showed that TIL Tim-3-expressing CD8+ T cells exhibited impaired Stat5 and p38 signaling pathway. Blocking the Tim-3 pathway restored cell proliferation and increased IFN-γ production in TIL CD4+ and CD8+ T cells of RCC. CONCLUSIONS: These results suggest that Tim-3 may be used as a novel target for increasing immune responses in RCC tumor microenvironment.
Authors: Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Minghua Li; Sherimay D Ablan; Chunhui Miao; Yi-Min Zheng; Matthew S Fuller; Paul D Rennert; Wendy Maury; Marc C Johnson; Eric O Freed; Shan-Lu Liu Journal: Proc Natl Acad Sci U S A Date: 2014-08-18 Impact factor: 11.205
Authors: Ken Koguchi; David E Anderson; Li Yang; Kevin C O'Connor; Vijay K Kuchroo; David A Hafler Journal: J Exp Med Date: 2006-06-05 Impact factor: 14.307
Authors: François Audenet; Adam M Farkas; Harry Anastos; Matthew D Galsky; Nina Bhardwaj; John P Sfakianos Journal: World J Urol Date: 2018-06-02 Impact factor: 4.226
Authors: David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri Journal: Nat Rev Clin Oncol Date: 2021-01-12 Impact factor: 66.675